Quantitative spectral quality assessment technique validated using intraoperative in vivo Raman spectroscopy measurements.
Raman spectroscopy
fluorescence
machine learning
signal processing
surgery
tissue optics
Journal
Journal of biomedical optics
ISSN: 1560-2281
Titre abrégé: J Biomed Opt
Pays: United States
ID NLM: 9605853
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
17
01
2020
accepted:
08
04
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
25
9
2021
Statut:
ppublish
Résumé
Ensuring spectral quality is prerequisite to Raman spectroscopy applied to surgery. This is because the inclusion of poor-quality spectra in the training phase of Raman-based pathology detection models can compromise prediction robustness and generalizability to new data. Currently, there exists no quantitative spectral quality assessment technique that can be used to either reject low-quality data points in existing Raman datasets based on spectral morphology or, perhaps more importantly, to optimize the in vivo data acquisition process to ensure minimal spectral quality standards are met. To develop a quantitative method evaluating Raman signal quality based on the variance associated with stochastic noise in important tissue bands, including C─C stretch, CH2 / CH3 deformation, and the amide bands. A single-point hand-held Raman spectroscopy probe system was used to acquire 315 spectra from 44 brain cancer patients. All measurements were classified as either high or low quality based on visual assessment (qualitative) and using a quantitative quality factor (QF) metric. Receiver-operator-characteristic (ROC) analyses were performed to evaluate the performance of the quantitative metric to assess spectral quality and improve cancer detection accuracy. The method can separate high- and low-quality spectra with a sensitivity of 89% and a specificity of 90% which is shown to increase cancer detection sensitivity and specificity by up to 20% and 12%, respectively. The QF threshold is effective in stratifying spectra in terms of spectral quality and the observed false negatives and false positives can be linked to limitations of qualitative spectral quality assessment.
Identifiants
pubmed: 32319263
pii: JBO-200014LRR
doi: 10.1117/1.JBO.25.4.040501
pmc: PMC7171512
doi:
Types de publication
Letter
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Subventions
Organisme : CIHR
Pays : Canada
Références
Oncotarget. 2017 May 30;8(22):36824-36831
pubmed: 28415660
Analyst. 2019 Nov 4;144(22):6517-6532
pubmed: 31647061
BJU Int. 2018 Aug;122(2):326-336
pubmed: 29542855
Photodiagnosis Photodyn Ther. 2013 Sep;10(3):207-19
pubmed: 23993846
Cancer Metastasis Rev. 2018 Dec;37(4):691-717
pubmed: 30569241
Cancer Res. 2017 Jul 15;77(14):3942-3950
pubmed: 28659435
Cancer Res. 2006 Mar 15;66(6):3317-22
pubmed: 16540686
Sci Transl Med. 2015 Feb 11;7(274):274ra19
pubmed: 25673764
Appl Spectrosc. 2010 Jun;64(6):595-600
pubmed: 20537226
Appl Spectrosc. 2007 Feb;61(2):117-29
pubmed: 17331302
J Biomed Opt. 2012 Jul;17(7):077002
pubmed: 22894515
Appl Spectrosc. 2012 Jun;66(6):650-5
pubmed: 22732535